Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, has recently announced the publication of data from its successful Phase 1 clinical trial evaluating Annamycin as a single agent treatment for relapsed or refractory Acute Myeloid Leukemia (AML). The findings of this study were published in the highly regarded British Journal of Cancer Research, after undergoing a thorough peer-re..